NCT07143864View on ClinicalTrials.gov

Efficacy and Safety of Stapokibart for Primary Cutaneous Amyloidosis

NANot yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 15, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Primary Cutaneous Amyloidosis
Interventions
BIOLOGICAL

Stapokibart

A humanized monoclonal antibody that targets the interleukin (IL)-4 receptor subunit alpha

OTHER

Placebo drug

Placebo drugs without Stapokibart

All Listed Sponsors
lead

First Affiliated Hospital of Chongqing Medical University

OTHER